MentalHealthDaily

1 mg Guanfacine for Self-Harm Thoughts in ADHD-PTSD-BPD Case

by GLOOM

MHD featured image for 1 mg guanfacine and self-harm thoughts in complex ADHD, PTSD, BPD, and ASD comorbidity.

A 2026 case report linked 1 mg nightly guanfacine modified-release to first-ever cessation of intrusive deliberate self-harm thoughts in a 16-year-old with attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD) traits, borderline personality disorder (BPD) traits, and post-traumatic stress disorder (PTSD). The same case became more interesting after the patient stopped taking guanfacine and the self-harm …

Ketamine Addiction After One Therapeutic Dose: How Rare Is It?

by GLOOM

Stylized illustration evoking the tension between ketamine's clinical promise for depression and its abuse liability, framed in muted rose and amber tones for the addiction topic.

Ketamine and its S-enantiomer esketamine (sold as Spravato) are now established treatments for treatment-resistant depression and acute suicidality. The standard safety pitch from sponsors and clinics: at single sub-anesthetic doses, in supervised settings, addiction risk is minimal. A new case report in BJPsych Open documents a patient for whom that pitch failed catastrophically — and …

Nortriptyline-Induced “Room Tilt Illusion”: A Rare Adverse Event of Antidepressants (2024 Case Report)

by GLOOM

Room Tilt Illusion (RTI) presents a perplexing challenge to both patients and physicians, transforming the familiar into the surreal as surroundings appear rotated or flipped. This rare condition, often linked to neurological or vestibular disorders, has recently been observed as an adverse effect of the antidepressant nortriptyline, used in treatment-resistant depression. A case report highlights …

Celecoxib Effective for Postpartum Depression in 34-Year-Old Woman (2023 Case Report)

by GLOOM

Postpartum depression (PPD) is a serious mental health issue affecting many new mothers, impacting their well-being and their ability to bond with their child. Recent research suggests that inflammation could play a crucial role in the development of depression, opening the door to innovative treatments. A new case report highlights the potential of celecoxib, an …

Marijuana Abuse & Early-Onset Frontotemporal Dementia: 34-Year-Old Male (Case Report)

by GLOOM

A 34-year-old man developed symptoms of frontotemporal dementia (FTD), a rare form of early-onset dementia, after using cannabis for two years. This case highlights the potential risks of long-term cannabis use on brain health, especially for vulnerable individuals. Key Facts: The 34-year-old man used cannabis for two years before experiencing personality changes and behavioral symptoms …

Fecal Microbiota Transplantation (FMT) for Depression Treatment: 2 Case Reports (Pilot Study)

by GLOOM

Fecal microbiota transplantation (FMT) aims to modify the gut microbiome and holds promise as a new treatment approach for major depressive disorder (MDD). Early case studies report improvements in depressive symptoms following fecal microbiota transplantation (FMT), but larger controlled trials are needed to substantiate its efficacy. Key Facts: Two patients with long-standing major depression received …

Case Report: Depression Treated with Deep Brain Focused Ultrasound (2023)

by GLOOM

Deep brain stimulation using focused ultrasound leads to rapid remission of severe depression in breakthrough patient case study. Key Facts: Focused ultrasound targeted and suppressed hyperactive areas linked to depression. Stimulation lasted just 64 minutes yet caused depression remission for over 6 weeks. Approach is noninvasive and precisely targeted with no side effects observed. Technology …